22UA:ETR
BioNTech SE - ADR
79,15 €
arrow_downward
−0,81%(−0,65) 1 p
15. okt, 13:43:00 GMT +2 · EUR
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse 22UA põhistatistika genereerimine…
Ava
79,40 €
Kõrge
79,40 €
Madal
78,75 €
Turu kapit.
22,27Â mld
Keskm. maht
26,31Â tuh
Maht
4,03Â tuh
52 näd kõrgeim
105,70 €
52 näd madalaim
68,30 €
Töötajate arv
8Â tuh
Ava
79,40 €
Kõrge
79,40 €
Madal
78,75 €
Turu kapit.
22,27Â mld
Keskm. maht
26,31Â tuh
Maht
4,03Â tuh
52 näd kõrgeim
105,70 €
52 näd madalaim
68,30 €
Töötajate arv
8Â tuh
Uudised
Veebiallikatest ja uudistepartneritelt
Pluang
·
16 tunni eest
BioNTech shares drop 7.13% after trial failure raises concerns over oncology program claims
Simply Wall Street
·
1 päeva eest
BioNTech Stock Faces Questions After Cancer Trial Missed Progression Free Survival Goal
TradingKey
·
1 päeva eest
Biontech SE Stock (BNTX) Closed Down by 7.13% on Oct 13: Drivers Behind the Movement
GuruFocus
·
1 päeva eest
BioNTech (BNTX) Shares Slide After BNT113 Vaccine Misses Progres
Profiil
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Teave üksuse BioNTech SE - ADR kohta